Concepedia

Blanca Homet Moreno

BH

50

Publications

10.5K

Citations

30

H-Index

2015

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of California, Los Angeles

Institut Gustave Roussy

Memorial Sloan Kettering Cancer Center

University of Washington

Blanca Homet Moreno is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and cancer therapeutics.

Top concepts

MedicineOncologyCancer TherapyRadiation OncologyUrologyMolecular OncologyClinical TrialsHealthPathologyPharmacotherapy

Publications per year

2015–2025

50

Publications

50

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Jesse M. Zaretsky, Ángel García-Díaz, Daniel Sanghoon Shin et al. · New England Journal of Medicine · 2016 · 3.1K citations · Full text

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Ángel García-Díaz, Daniel Sanghoon Shin, Blanca Homet Moreno et al. · Cell Reports · 2017 · 1.8K citations · Full text

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Thomas Powles, Begoña P. Valderrama, Shilpa Gupta et al. · New England Journal of Medicine · 2024 · 764 citations

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in <i>BRAF</i> <sup> <i>V600E</i> </sup> melanoma

Siwen Hu‐Lieskovan, Stephen Mok, Blanca Homet Moreno et al. · Science Translational Medicine · 2015 · 562 citations · Full text

Rows per page

1–5 of 50